Paycor HCM, Inc. (PYCR)
Apr 14, 2025 - PYCR was delisted (reason: acquired by PAYX)
22.49
0.00 (0.00%)
Inactive · Last trade price on Apr 11, 2025
Sage Therapeutics Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2020 |
Operating Revenue | 643.83 | 602.39 | 518.87 | 427.03 | 350.96 | 317.62 | Upgrade |
Other Revenue | 55.9 | 52.56 | 33.82 | 2.36 | 1.82 | 10.29 | Upgrade |
| 699.73 | 654.95 | 552.69 | 429.39 | 352.78 | 327.91 | Upgrade | |
Revenue Growth (YoY) | 15.72% | 18.50% | 28.72% | 21.72% | 7.58% | 12.50% | Upgrade |
Cost of Revenue | 238.14 | 223.24 | 187.14 | 168.19 | 154.49 | 139.68 | Upgrade |
Gross Profit | 461.6 | 431.71 | 365.55 | 261.2 | 198.29 | 188.23 | Upgrade |
Selling, General & Admin | 414.06 | 425.76 | 411.66 | 348.62 | 251.6 | 237.07 | Upgrade |
Research & Development | 66.5 | 61.42 | 54.26 | 43.14 | 36.02 | 45.87 | Upgrade |
Operating Expenses | 480.55 | 487.18 | 465.92 | 391.76 | 287.62 | 282.94 | Upgrade |
Operating Income | -18.95 | -55.47 | -100.37 | -130.57 | -89.33 | -94.71 | Upgrade |
Interest Expense | -4.56 | -4.68 | -4.64 | -0.54 | -2.54 | -1.78 | Upgrade |
Interest & Investment Income | 7.19 | 4.74 | 4.63 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | 0.81 | - | - | 1.43 | -1.42 | 9 | Upgrade |
EBT Excluding Unusual Items | -15.5 | -55.41 | -100.37 | -129.67 | -93.29 | -87.49 | Upgrade |
Merger & Restructuring Charges | - | - | -2.5 | - | - | - | Upgrade |
Other Unusual Items | -4.34 | -4.31 | -1.79 | -8.92 | - | - | Upgrade |
Pretax Income | -19.84 | -59.72 | -104.66 | -138.59 | -93.29 | -87.49 | Upgrade |
Income Tax Expense | 1.59 | -0.77 | -11.45 | -30.57 | -20.81 | -20.18 | Upgrade |
Earnings From Continuing Operations | -21.43 | -58.94 | -93.22 | -108.02 | -72.48 | -67.3 | Upgrade |
Minority Interest in Earnings | - | - | - | -11.62 | -24.44 | -22.89 | Upgrade |
Net Income | -21.43 | -58.94 | -93.22 | -119.64 | -96.92 | -90.19 | Upgrade |
Net Income to Common | -21.43 | -58.94 | -93.22 | -119.64 | -96.92 | -90.19 | Upgrade |
Shares Outstanding (Basic) | 179 | 178 | 176 | 173 | 146 | 152 | Upgrade |
Shares Outstanding (Diluted) | 179 | 178 | 176 | 173 | 146 | 152 | Upgrade |
Shares Change (YoY) | 1.01% | 0.92% | 1.97% | 17.95% | -3.53% | - | Upgrade |
EPS (Basic) | -0.12 | -0.33 | -0.53 | -0.69 | -0.66 | -0.59 | Upgrade |
EPS (Diluted) | -0.12 | -0.33 | -0.53 | -0.69 | -0.66 | -0.59 | Upgrade |
Free Cash Flow | 115.56 | 86.54 | 43.07 | 22.37 | 7.44 | -7.75 | Upgrade |
Free Cash Flow Per Share | 0.65 | 0.49 | 0.24 | 0.13 | 0.05 | -0.05 | Upgrade |
Gross Margin | 65.97% | 65.92% | 66.14% | 60.83% | 56.21% | 57.40% | Upgrade |
Operating Margin | -2.71% | -8.47% | -18.16% | -30.41% | -25.32% | -28.88% | Upgrade |
Profit Margin | -3.06% | -9.00% | -16.87% | -27.86% | -27.47% | -27.51% | Upgrade |
Free Cash Flow Margin | 16.52% | 13.21% | 7.79% | 5.21% | 2.11% | -2.36% | Upgrade |
EBITDA | 73.67 | 52.31 | 6.9 | -22.15 | 43.2 | 31.62 | Upgrade |
EBITDA Margin | 10.53% | 7.99% | 1.25% | -5.16% | 12.25% | 9.64% | Upgrade |
D&A For EBITDA | 92.63 | 107.78 | 107.27 | 108.42 | 132.54 | 126.32 | Upgrade |
EBIT | -18.95 | -55.47 | -100.37 | -130.57 | -89.33 | -94.71 | Upgrade |
EBIT Margin | -2.71% | -8.47% | -18.16% | -30.41% | -25.32% | -28.88% | Upgrade |
Revenue as Reported | 699.73 | 654.95 | 552.69 | 429.39 | 352.78 | 327.91 | Upgrade |
Advertising Expenses | - | 34.34 | 29.96 | 22.13 | 17.96 | 14.87 | Upgrade |
Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.